½ÃÀ庸°í¼­
»óǰÄÚµå
1370643

ÁÖ»ç ÇÇÀÓ¾à ½ÃÀå - À¯Çüº°, ¿¬·É´ëº°, ÀÛ¿ë ½Ã°£º°, ÃÖÁ¾»ç¿ëÀÚº°, ¼¼°è ¿¹Ãø(2023-2032³â)

Injectable Contraceptives Market - By Type (Progesterone-only Injectables {Depot Medroxyprogesterone Acetate}), Age Group (15-24 Years, 25-34 Years), Duration of Action (Short-acting Injectable Contraceptives), End-user, Global Forecast, 2023-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 208 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÁÖ»ç ÇÇÀÓ¾à ¼¼°è ½ÃÀåÀº 2023³âºÎÅÍ 2032³â±îÁö 3.5%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ÁÖ»ç ÇÇÀÓ¾à ºÐ¾ßÀÇ ±â¼ú Çõ½Å°ú ¿¬±¸ ¹ß°ßÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾÷°è´Â È®Àå Ãß¼¼¿¡ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 10¿ù Àεµ ÀÇÇבּ¸À§¿øÈ¸(ICMR)´Â ÇÇÀÓ¾à ºÐ¾ß¿¡¼­ ȹ±âÀûÀÎ °³¹ßÀ» ÅëÇØ ¼¼°è ÃÖÃÊÀÇ ÁÖ»çÇü ³²¼º ÇÇÀӾ࿡ ´ëÇÑ ÀÓ»ó½ÃÇèÀ» ¼º°øÀûÀ¸·Î ¸¶ÃƽÀ´Ï´Ù. ÀÌ ÀÓ»ó½ÃÇèÀº ÀÌ ÇÇÀÓ¹ýÀÇ ¾ÈÀü¼º°ú ¶Ù¾î³­ È¿´ÉÀ» ÀÔÁõÇßÀ¸¸ç, ½É°¢ÇÑ ºÎÀÛ¿ëÀÌ ¾ø´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. 25¼¼ºÎÅÍ 40¼¼±îÁö 303¸íÀÇ Èĺ¸ÀÚ°¡ ÀÓ»ó 3»ó ½ÃÇè¿¡ Âü¿©ÇßÀ¸¸ç, ICMRÀÇ ÀÓ»ó½ÃÇè °á°ú´Â ÃÖ±Ù ±¹Á¦ÀûÀ¸·Î Á¢±Ù °¡´ÉÇÑ Andrology Àú³Î¿¡ °ÔÀçµÇ¾ú½À´Ï´Ù.

Á¦Çü, Àü´Þ ¹æ¹ý ¹× È¿°úÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î ¿©¼º°ú ³²¼ºÀÇ ÇÇÀÓ ¼±ÅñÇÀÌ ³Ð¾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¼±ÅÃÀÇ ÆøÀ» ³ÐÈú »Ó¸¸ ¾Æ´Ï¶ó ÇÇÀÓ¾àÀÇ ÆíÀǼº°ú ½Å·Ú¼ºÀ» Çâ»ó½ÃÄÑ ÇÇÀÓ¾à ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

º¹ÇÕ ÇÇÀÓ¾à ºÎ¹®Àº 2023³âºÎÅÍ 2032³â±îÁö Å« ¹ßÀüÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Á¦Á¦¿¡´Â ¿©¼º¿¡°Ô ¸Å¿ì È¿°úÀûÀÎ ÇÇÀÓ ¿É¼ÇÀ» Á¦°øÇϴ ȣ¸£¸ó Á¶ÇÕÀÌ Æ÷ÇԵǾî ÀÖÀ¸¸ç, CICÀÇ ÆíÀǼº°ú È¿´ÉÀº ºÎÀÛ¿ë °¨¼Ò¿Í ÇÔ²² CICÀÇ Àαâ Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿©¼ºµéÀÌ ½Å·ÚÇÒ ¼ö ÀÖ´Â ÇÇÀÓ ¿É¼ÇÀ» ãÀ¸¸é¼­ ÁÖ»ç¿ë º¹ÇÕ ÇÇÀӾ࿡ ´ëÇÑ ¼ö¿ä´Â ÁÖ»ç¿ë ÇÇÀÓ¾à ½ÃÀå Àü¸Á¿¡¼­ °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ºÎÀΰú Ŭ¸®´Ð ºÐ¾ß´Â 2023³âºÎÅÍ 2032³â±îÁö ´«¿¡ ¶ç´Â CAGRÀ» ±â·ÏÇÒ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀÇ·á ½Ã¼³Àº Á¡Á¡ ´õ ¸¹Àº ¿©¼º¿¡°Ô Æí¸®Çϰí È¿°úÀûÀÎ ÇÇÀÓ ¹æ¹ýÀ¸·Î ÁÖ»ç ÇÇÀÓ¾àÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. »êºÎÀΰú Ŭ¸®´Ð¿¡¼­ Á¦°øÇÏ´Â Àü¹® Áö½Ä°ú ¼­ºñ½º´Â Àü¹®ÀûÀÎ Áöµµ¿Í Ä¡·á¸¦ ¿øÇÏ´Â »ç¶÷µé¿¡°Ô ´ç¿¬ÇÑ ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â º¸´Ù Ä£¼÷ÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ÇÇÀÓ¹ýÀ¸·ÎÀÇ ±¤¹üÀ§ÇÑ º¯È­¸¦ ¹Ý¿µÇϸç, ÇÇÀÓ¾à ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

À¯·´ÀÇ ÁÖ»ç ÇÇÀÓ¾à ½ÃÀåÀº 2023³âºÎÅÍ 2032³â±îÁö »ó´çÇÑ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ÀÌ Áö¿ªÀÇ ¼±ÁøÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó¿Í ÇÇÀÓ ¿É¼Ç¿¡ ´ëÇÑ ¿©¼ºµéÀÇ ÀνÄÀÌ ³ô¾ÆÁ³±â ¶§¹®ÀÔ´Ï´Ù. À¯·´ ¿©¼ºµéÀº ¾ÈÀüÇÏ°í Æí¸®ÇÑ ÇÇÀÓ¹ýÀ¸·Î ÁÖ»ç ÇÇÀÓ¿¡ ÁÖ¸ñÇϰí ÀÖ½À´Ï´Ù. »ý½Ä°Ç°­°ú Á¤º¸¿¡ ÀÔ°¢ÇÑ ¼±Åÿ¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ À¯·´ ÇÇÀӾ࿡ ´ëÇÑ ¼ö¿ä°¡ È®´ëµÇ°í ÀÖÀ¸¸ç, ¼¼°è ½ÃÀå¿¡¼­µµ µÎµå·¯Áø ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÁÖ»ç ÇÇÀÓ¾à ½ÃÀå ÀλçÀÌÆ®

  • ¾÷°è »óȲ
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • °¡Á· °èȹ¿¡ ´ëÇÑ ÀÎ½Ä È®»ê
      • ÁÖ»ç ÇÇÀÓ¾àÀÇ ÀÌÁ¡¿¡ °üÇÑ ÀÎ½Ä »ó½Â
      • ÁÖ»ç ÇÇÀӾ࿡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½Ã۱â À§ÇÑ Á¤ºÎ³ª ±âŸ Á¶Á÷¿¡ ÀÇÇÑ ´ëó
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©¿Í °úÁ¦
      • ÁÖ»ç ÇÇÀӾ࿡ µû¸¥ ÈÄÀ¯Áõ
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • COVID-19 ¿µÇ⠺м®
  • ±ÔÁ¦ »óȲ
  • Porters ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï »óȲ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ¼¼°è ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ÁÖ»ç ÇÇÀÓ¾à ½ÃÀå : À¯Çüº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : À¯Çüº°
  • ÇÁ·Î°Ô½ºÅ×·Ð Àü¿ë ÁÖ»çÁ¦
    • ¾Æ¼¼Æ®»ê ¸Þµå·Ï½ÃÇÁ·Î°Ô½ºÅ×·Ð ÁÖ»çÁ¦
    • ¿¡³­Æ®»ê ³ë¸£¿¡Æ¼½ºÅ×·Ð
  • º¹ÇÕÇü ÁÖ»ç ÇÇÀÓ¾à

Á¦6Àå ÁÖ»ç ÇÇÀÓ¾à ½ÃÀå : ¿¬·ÉÃþº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : ¿¬·ÉÃþº°
  • 15-24¼¼
  • 25-34¼¼
  • 35-44¼¼
  • 44¼¼ ÀÌ»ó

Á¦7Àå ÁÖ»ç ÇÇÀÓ¾à ½ÃÀå : ÀÛ¿ë ½Ã°£º°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : ÀÛ¿ë ½Ã°£º°
  • ´Ü½Ã°£ ÀÛ¿ëÇü ÁÖ»ç ÇÇÀÓ¾à
  • Àå½Ã°£ ÀÛ¿ëÇü ÁÖ»ç ÇÇÀÓ¾à

Á¦8Àå ÁÖ»ç ÇÇÀÓ¾à ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : ÃÖÁ¾»ç¿ëÀÚº°
  • º´¿ø
  • ºÎÀΰú Ŭ¸®´Ð
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦9Àå ÁÖ»ç ÇÇÀÓ¾à ½ÃÀå : Áö¿ªº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ±â¾÷ °³¿ä

  • Pfizer Inc.
  • Amphastar Pharmaceutical Inc.
  • Zhejiang Xianju Pharmaceutical Co., Ltd
  • Eugia Pharma
  • Mylan Labs Ltd
  • Bayer Plc
  • Teva Pharms USA
  • PT Tunggal
  • Incepta Pharmaceuticals
  • Baxter International Inc.
ksm 23.11.15

Global Injectable Contraceptives Market will witness 3.5% CAGR between 2023 and 2032. The industry is set on expansion due to the growing number of innovations and research discoveries in the realm of injectable contraceptives. For instance, in October 2023, a groundbreaking development in the contraceptive field came from the Indian Council of Medical Research (ICMR), which successfully concluded clinical trials for the world's pioneering injectable male contraceptive. These trials demonstrated both safety and remarkable effectiveness of the method, devoid of any significant adverse effects. The phase-3 trials involved 303 candidates aged between 25 and 40 years. The results of ICMR's clinical trials were recently published in the internationally accessible Andrology journal.

Ongoing advancements in formulation, delivery methods, and efficacy are expanding contraceptive options for women and men. These innovations are not only broadening choice but also improving the convenience and reliability of injectable contraceptives, thus fueling the injectable contraceptive market growth.

The overall Injectable Contraceptives Market is classified based on type, end-user, and region.

Combined injectable contraceptives segment will undergo significant development from 2023 to 2032. These formulations include a combination of hormones that offer highly effective birth control options for women. The convenience and efficacy of CICs, in line with reduced side effects, have contributed to their increasing popularity. As women seek reliable contraceptive choices, the demand for combined injectable contraceptives continues to grow in the injectable contraceptives market outlook.

Gynaecology clinics segment will register a notable CAGR from 2023 to 2032. These healthcare facilities are increasingly offering injectable contraceptives as a convenient and effective birth control option for women. The specialized knowledge and services provided in gynaecology clinics make them a natural choice for those seeking expert guidance and care. This trend reflects the broader shift toward accessible and reliable contraceptive solutions, contributing to the injectable contraceptives market expansion.

Europe injectable contraceptives market will showcase an appreciable CAGR from 2023 to 2032. This is attributed to the region's progressive healthcare infrastructure and the increasing awareness among women regarding contraceptive options. European women are turning to injectable contraceptives as a safe and convenient choice. With a focus on reproductive health and informed choices, Europe's demand for injectable contraceptives will grow, making it a prominent segment within the global market.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market definition
  • 1.2 Base estimates & calculations
  • 1.3 Forecast calculation
  • 1.4 Covid-19 impact analysis at global level
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Secondary
      • 1.6.1.1 Paid sources
      • 1.6.1.2 Public sources
    • 1.6.2 Primary

Chapter 2 Executive Summary

  • 2.1 Injectable contraceptives industry 360 degree synopsis, 2018 - 2032 (USD Million)
    • 2.1.1 Business trends
    • 2.1.2 Regional trends
    • 2.1.3 Type trends
    • 2.1.4 Age group trends
    • 2.1.5 Duration of action trends
    • 2.1.6 End-user trends

Chapter 3 Injectable Contraceptives Market Insights

  • 3.1 Industry landscape, 2018 - 2032 (USD Million)
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rise in awareness about family planning
      • 3.2.1.2 Increasing awareness about benefits of injectable contraceptives
      • 3.2.1.3 Initiatives by government and other organizations to increase access to injectable contraceptives
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 After effects associated with injectable contraceptives
  • 3.3 Growth potential analysis
    • 3.3.1 By type
    • 3.3.2 By age group
    • 3.3.3 By duration of action
    • 3.3.4 By end-user
  • 3.4 COVID-19 impact analysis
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Global company market share analysis, 2022
  • 4.4 Competitive positioning matrix, 2022
  • 4.5 Strategic dashboard, 2022

Chapter 5 Injectable Contraceptives Market, By Type, 2018 - 2032 (USD Million)

  • 5.1 Key trends, by type
  • 5.2 Progesterone-only injectables
    • 5.2.1 Depot medroxyprogesterone acetate
    • 5.2.2 Norethisterone enanthate
  • 5.3 Combined injectable contraceptives

Chapter 6 Injectable Contraceptives Market, By Age Group, 2018 - 2032 (USD Million)

  • 6.1 Key trends, by age group
  • 6.2 15-24 years
  • 6.3 25-34 years
  • 6.4 35-44 years
  • 6.5 Above 44 years

Chapter 7 Injectable Contraceptives Market, By Duration of Action, 2018 - 2032 (USD Million)

  • 7.1 Key trends, by duration of action
  • 7.2 Short-acting injectable contraceptives
  • 7.3 Long-acting injectable contraceptives

Chapter 8 Injectable Contraceptives Market, By End-user, 2018 - 2032 (USD Million)

  • 8.1 Key trends, by end-user
  • 8.2 Hospital
  • 8.3 Gynecology clinics
  • 8.4 Other end-users

Chapter 9 Injectable Contraceptives Market, By Region, 2018 - 2032 (USD Million)

  • 9.1 Key trends, by region
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East & Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

  • 10.1 Pfizer Inc.
  • 10.2 Amphastar Pharmaceutical Inc.
  • 10.3 Zhejiang Xianju Pharmaceutical Co., Ltd
  • 10.4 Eugia Pharma
  • 10.5 Mylan Labs Ltd
  • 10.6 Bayer Plc
  • 10.7 Teva Pharms USA
  • 10.8 PT Tunggal
  • 10.9 Incepta Pharmaceuticals
  • 10.10 Baxter International Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦